Canagliflozin Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Case Report: Post-gastrectomy reactive hyperinsulinemic hypoglicaemia: glucose trends before and after canagliflozin treatment
We report the case of a 37-year-old non diabetic man who frequently presented symptoms of hypoglycaemia in the postprandial period. In 2012, he underwent Roux en-Y gastric bypass (RYGB) and after two years, he started to experience typical symptoms of reactive hyperinsulinaemic hypoglycaemia. We suggested healthy modifications of dietary habits and periodic follow-up visits with a dietitian. After three months, the patient still presented symptoms of reactive hypoglycaemia; we provided him with Flash Glucose Monitoring (FGM) to assess trend of glucose levels in interstitial fluid during the day and we decided to introduce ...
Source: Frontiers in Endocrinology - August 14, 2023 Category: Endocrinology Source Type: research

A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes
CONCLUSION: Bexagliflozin appears safe and effective as monotherapy and add-on pharmacological therapy for the treatment of T2D.PMID:37568270 | DOI:10.1177/10600280231190443 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - August 12, 2023 Category: Drugs & Pharmacology Authors: Kevin Cowart Scott Coon Nicholas W Carris Source Type: research

The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction
CONCLUSIONS: The treatment of HFpEF has made progress, but there is still work to be done. Now, SGLT2 inhibitor therapy can be used to further help with symptom control and reduce overall hospitalizations for heart failure.PMID:37542422 | DOI:10.1177/10600280231189508 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - August 5, 2023 Category: Drugs & Pharmacology Authors: Jessica A Starr Nathan A Pinner Source Type: research

Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, in-vitro , in silico , and in-vivo study
Drug Deliv. 2023 Dec;30(1):2241665. doi: 10.1080/10717544.2023.2241665.ABSTRACTCanagliflozin (CFZ) is a sodium-glucose cotransporter-2 inhibitor (SGLT2) that lowers albuminuria in type-2 diabetic patients, cardiovascular, kidney, and liver disease. CFZ is classified as class IV in the Biopharmaceutical Classification System (BCS) and is characterized by low permeability, solubility, and bioavailability, most likely attributed to hepatic first-pass metabolism. Nanocrystal-based sublingual formulations were developed in the presence of sodium caprate, as a wetting agent, and as a permeability enhancer. This formulation is su...
Source: Drug Delivery - August 4, 2023 Category: Drugs & Pharmacology Authors: Sammar Fathy Elhabal Mohamed A El-Nabarawi Nashwa Abdelaal Mohamed Fathi Mohamed Elrefai Shrouk A Ghaffar Mohamed Mansour Khalifa Passant M Mohie Dania S Waggas Ahmed Mohsen Elsaid Hamdan Samar Zuhair Alshawwa Essa M Saied Nahla A Elzohairy Tayseer Elnawa Source Type: research

Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes
Underlying molecular mechanisms of the kidney protective effects of sodium glucose co-transporter 2 (SGLT2) inhibitors are not fully elucidated. Therefore, we studied the association between urinary epidermal growth factor (uEGF), a mitogenic factor involved in kidney repair, and kidney outcomes in patients with type 2 diabetes (T2D). The underlying molecular mechanisms of the SGLT2 inhibitor canagliflozin on EGF using single-cell RNA sequencing from kidney tissue was examined. Urinary EGF-to-creatinine ratio (uEGF/Cr) was measured in 3521 CANagliflozin cardioVascular Assessment Study (CANVAS) participants at baseline and ...
Source: Kidney International - August 3, 2023 Category: Urology & Nephrology Authors: Taha Sen, Wenjun Ju, Viji Nair, Patricia Ladd, Rajasree Menon, Edgar A. Otto, Laura Pyle, Tim Vigers, Robert G. Nelson, Clare Arnott, Bruce Neal, Michael K. Hansen, Matthias Kretzler, Petter Bjornstad, Hiddo J.L. Heerspink Tags: clinical investigation Source Type: research

Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study)
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are considered to have the potential to maintain renal function by correcting glomerular hypertension in patients with diabetic kidney disease (DKD). The aim ... (Source: BMC Nephrology)
Source: BMC Nephrology - August 3, 2023 Category: Urology & Nephrology Authors: Sawako Kato, Yachiyo Kuwatsuka, Masahiko Ando, Yoshitaka Tatematsu, Nobuhiro Nishibori and Shoichi Maruyama Tags: Study protocol Source Type: research